Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are used as standard therapies for advanced nonsmall cell lung cancer (NSCLC) patients with EGFR mutation positive. Because these targeted therapies could cause tumor necrosis and shrinkage, the purpose of the study is to sear...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: He, Xiaobo, Zhang, Yang, Ma, Yuxiang, Zhou, Ting, Zhang, Jianwei, Hong, Shaodong, Sheng, Jin, Zhang, Zhonghan, Yang, Yunpeng, Huang, Yan, Zhang, Li, Zhao, Hongyun
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2016
Assuntos:
5700
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979775/
https://ncbi.nlm.nih.gov/pubmed/27495021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004176
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados